Clinical Trial

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the efficacy and safety of Pembrolizumab in combination with Lenvatinib in recurrent, mismatch repair-proficient endometrial cancer after failure of first-line therapy with a platinum-based doublet chemotherapy and immunotherapy.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2031-06-01 -> 2031-09-01 2026-07-14
minor Completion pushed: 2031-06-01 -> 2031-09-01 2026-07-14
Trial Details
NCT Number NCT07594015
Lead Sponsor University of Miami
Conditions Recurrent Endometrial Cancer
Enrollment 46 participants
Start Date 2026-09-01
Primary Completion 2031-09-01 (estimated)
Study Completion 2031-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-13